TECregen

Basel, Basel-City, Switzerland · Biotechnology, Health Care · 10 employees

TECregen is pioneering thymus rejuvenation to address conditions driven by impaired T-cell responses. The company’s innovative approach focuses on revitalizing and expanding thymic epithelial cells (TECs) to replenish T cells and achieve durable improvements in immune function. By developing a pipeline of differentiated thymopoietic biologics, TECregen aims to strengthen immune recovery following

See plans & pricing → Track TECregen’s funding, hiring, and signals — with verified contacts — on Fundz.